P068 NATALIZUMAB MAINTAINS REMISSION FOR 2 YEARS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE AND IN THOSE WITH PRIOR INFLIXIMAB EXPOSURE: RESULTS FROM AN OPEN-LABEL EXTENSION STUDY

✍ Scribed by G. D'Haens; F. Baert; P. Rutgeerts; R. Panaccione

• Book ID: 119637055
• Publisher: Oxford University Press
• Year: 2007
• Weight: 58 KB
• Volume: 1
• Category: Article
• ISSN: 1873-9954
• DOI: 10.1016/s1873-9954(07)70080-0